Market Closed -
Toronto S.E.
18:57:58 28/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.99
CAD
|
-1.00%
|
|
-1.00%
|
-23.26%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
48.39
|
190.7
|
175.8
|
66.39
|
51.12
|
Enterprise Value (EV)
1 |
48.39
|
190.7
|
175.8
|
66.39
|
51.12
|
P/E ratio
|
-13.9
x
|
-57
x
|
-32.2
x
|
-129
x
|
-9.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
14,814
x
|
27,129
x
|
-
|
183
x
|
EV / Revenue
|
-
|
14,814
x
|
27,129
x
|
-
|
183
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
22.5
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
38,715
|
47,784
|
49,659
|
51,464
|
51,641
|
Reference price
2 |
1.250
|
3.990
|
3.540
|
1.290
|
0.9900
|
Announcement Date
|
29/04/21
|
26/04/22
|
27/04/23
|
23/04/24
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
-
|
0.0129
|
0.00648
|
-
|
0.28
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-3.011
|
-
|
-
|
-5.3
|
Operating Margin
|
-
|
-23,396.35%
|
-
|
-
|
-1,892.68%
|
Earnings before Tax (EBT)
|
-
|
-3.064
|
-
|
-
|
-
|
Net income
1 |
-3.31
|
-3.064
|
-
|
-
|
-5.138
|
Net margin
|
-
|
-23,806.37%
|
-
|
-
|
-1,834.82%
|
EPS
2 |
-0.0900
|
-0.0700
|
-0.1100
|
-0.0100
|
-0.1000
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/04/21
|
26/04/22
|
27/04/23
|
23/04/24
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
0.00145
|
0.00372
|
0.00131
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.28
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-1.082
|
-0.9996
|
-1.422
|
-2.172
|
-1.084
|
-1.116
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.9175
|
Operating Margin
|
-
|
-68,937.24%
|
-38,212.63%
|
-165,780.15%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-327.68%
|
Earnings before Tax (EBT)
|
-1.096
|
-1.01
|
-1.422
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-1.096
|
-1.01
|
-1.422
|
-2.133
|
-1.002
|
-1.046
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.8785
|
Net margin
|
-
|
-69,631.72%
|
-38,212.63%
|
-162,821.37%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-313.75%
|
EPS
2 |
-0.0200
|
-0.0200
|
-0.0300
|
-0.0400
|
-0.0200
|
-0.0200
|
-0.0200
|
-0.0400
|
0.0700
|
-0.0200
|
-0.0200
|
-0.0400
|
-0.0200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/04/22
|
26/05/22
|
26/08/22
|
29/11/22
|
27/04/23
|
26/05/23
|
29/08/23
|
29/11/23
|
23/04/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-56.8%
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
0.1800
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
29/04/21
|
26/04/22
|
27/04/23
|
23/04/24
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -23.26% | 37.49M | | +54.05% | 58.71B | | -2.02% | 41.31B | | +36.84% | 39.2B | | -10.22% | 27.4B | | +13.42% | 26.55B | | -21.60% | 18.98B | | +2.89% | 12.51B | | +22.40% | 11.94B | | +27.49% | 12.08B |
Other Biotechnology & Medical Research
|